Lukashina T V, Mukhamedov Kh A, Stoilov L D, Pankova S S
Probl Endokrinol (Mosk). 1985 Jul-Aug;31(4):3-5.
Divascan (iprasochrome), a drug designed by GDR pharmacologists, brings about a positive effect in the management of diabetic microangiopathies, particularly at early stages. Altogether 22 patients with diabetes mellitus, types I and II, were on divascan therapy. Before and after treatment the patients were subjected to clinical and ophthalmoscopic studies including the determination of microcirculation in the conjunctiva, renal function, the level of serotonin, its precursors and the main metabolite. The optimal dose of divascan is 7.5-10 mg/day, the period of therapy not less than 3 months followed by the use of maintenance doses. The drug produces no side effects.
“迪瓦司坎”（异丙色胺）是民主德国药理学家研制的一种药物，对糖尿病微血管病变的治疗有积极效果，尤其是在早期阶段。共有22例I型和II型糖尿病患者接受了迪瓦司坎治疗。治疗前后，对患者进行了临床和眼底检查，包括测定结膜微循环、肾功能、血清素水平、其前体及主要代谢产物。迪瓦司坎的最佳剂量为7.5 - 10毫克/天，治疗期不少于3个月，之后使用维持剂量。该药物无副作用。
